Holen Sie sich die Stockscreener-App
14.90
0.47%
-0.10
Schlusskurs vom Vortag:
$15.00
Offen:
$14.74
24-Stunden-Volumen:
21,768
Relative Volume:
0.39
Marktkapitalisierung:
$407.36M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-102.09M
KGV:
-14.19
EPS:
-1.05
Netto-Cashflow:
$-108.72M
1W Leistung:
+12.34%
1M Leistung:
+51.27%
6M Leistung:
+103.96%
1J Leistung:
+330.53%
1-Tages-Spanne:
$14.74
$15.07
1-Wochen-Bereich:
$13.77
$16.98
52-Wochen-Spanne:
$2.2045
$16.98
Dbv Technologies Adr Stock (DBVT) Company Profile
Firmenname
Dbv Technologies Adr
Sektor
Branche
Telefon
33(0)155427878
Adresse
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Vergleichen Sie DBVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
14.87 | 410.59M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.81 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-29 | Fortgesetzt | Goldman | Sell |
| 2023-01-04 | Hochstufung | Societe Generale | Hold → Buy |
| 2022-12-16 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-09-14 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-01-22 | Herabstufung | Societe Generale | Hold → Sell |
| 2020-11-02 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-08-06 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-17 | Herabstufung | Stifel | Buy → Hold |
| 2020-01-09 | Hochstufung | Stifel | Hold → Buy |
| 2019-12-16 | Eingeleitet | Citigroup | Buy |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Eingeleitet | Goldman | Buy |
| 2018-12-20 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Herabstufung | Jefferies | Buy → Hold |
| 2018-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-10-31 | Hochstufung | Societe Generale | Sell → Hold |
| 2017-10-24 | Herabstufung | Societe Generale | Buy → Sell |
| 2017-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Eingeleitet | Deutsche Bank | Buy |
| 2017-03-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2016-09-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-03 | Eingeleitet | Barclays | Overweight |
| 2015-10-23 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Consensus Target Price from Brokerages - Defense World
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - Placera.se
DBV Technologies raises $30 million through ADS sale on Nasdaq - Investing.com
DBV Technologies Announces Sale of approximately $30 - GlobeNewswire
$30M ADS Sale: DBV Technologies Issues 2,307,692 ADSs via ATM Program on Nasdaq and Euronext Paris - Stock Titan
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
DBV Technologies Announces Board Member Resignation - MSN
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
European ADRs In The US See Modest Gains On Health And Tech - Finimize
What drives DBV Technologies SA DBV stock priceLarge Cap Stability Picks & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
Can DBV Technologies S.A. Depositary Receipt stock reach $100 price target2025 Market Trends & Expert Curated Trade Ideas - newser.com
DBV Technologies Announces Resignation of Board Member - GlobeNewswire
Biotech Board Shake-up: DBV Technologies Director Exits Amid VIASKIN Peanut Patch Development - Stock Titan
DBV Technologies stock rating reiterated at Market Outperform by JMP - Investing.com
Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $14.75 - Defense World
Analysts Set DBV Technologies S.A. (NASDAQ:DBVT) Price Target at $14.75 - Defense World
DBV Technologies Establishes an At-The-Market Program on Nasdaq - MarketScreener
DBV Technologies Launches $150M ATM Equity Offering - The Globe and Mail
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq - Placera.se
DBV Technologies S.A. - Via Ritzau
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Clinical-Stage Biotech DBV Technologies Featured at H.C. Wainwright Global Investment Conference - Stock Titan
Market reaction to DBV Technologies S.A. Depositary Receipt’s recent newsQuarterly Portfolio Review & High Conviction Trade Alerts - Newser
Should you hold or exit DBV Technologies S.A. Depositary Receipt nowJuly 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
European ADRs End Lower As Healthcare And Telecom Diverge - Finimize
European ADRs: A Strategic Buy Amid Macroeconomic Shifts and Undervalued Sectors - AInvest
Will DBV Technologies S.A. Depositary Receipt continue its uptrendPortfolio Growth Summary & Long-Term Growth Stock Strategies - Newser
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
European ADRs Climb On Solid Gains From Health And Tech Stocks - Finimize
Published on: 2025-08-19 16:04:03 - Newser
Using portfolio simulators with DBV Technologies S.A. Depositary Receipt includedQuarterly Profit Report & Daily Profit Focused Screening - Newser
DBV Technologies S.A. Depositary Receipt Moves Into Bullish Territory Based on MACD2025 Market Trends & Precise Swing Trade Alerts - metal.it
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest
Peanut Allergy Treatment Market Report 2025-2033, with Key Player Profiles for Aimmune Therapeutics, DBV Technologies, Sanofi, ALK-Abello, Prota Therapeutics, Camallergy, Aravax, and Genentech - Yahoo Finance
European ADRs Edge Higher While Sector Winners And Losers Diverge - Finimize
European ADRs Face Choppy Trading As Sentiment Sours - Finimize
Does DBV Technologies S.A. Depositary Receipt fit your quant trading modelAlpha Generation Strategy with Low Volatility - Newser
HC Wainwright Lowers Earnings Estimates for DBV Technologies - Defense World
European Stocks Dip As US Holders Turn Cautious - Finimize
DBV Technologies Maintains Buy Rating with €6.00 Target from Kepler Capital's Justine Telliez - AInvest
DBV Technologies Announces Filing of 2025 Half-Year Report - AInvest
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report - GlobeNewswire
DBV Technologies Releases Latest Financial Report: Food Allergy Treatment Progress Updates Inside - Stock Titan
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results - GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times
DBV Technologies Liquidity Contract Update: Over €3M in Trading Volume Reveals Market Activity - Stock Titan
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Tuesday - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Average PT from Analysts - Defense World
Finanzdaten der Dbv Technologies Adr-Aktie (DBVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dbv Technologies Adr-Aktie (DBVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):